


PHARMACEUTICAL 2022

Annovis Bio Inc. Rank 64 of 466










PHARMACEUTICAL 2022





The relative strengths and weaknesses of Annovis Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Annovis Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Annovis Bio Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 183% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	46,001
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,507
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	50
Other Revenues	0
Property and Equipment	0
Research and Development	8,479
Selling, General and Administrative Expense	6,058

Output Variable	Value in 1000 USD
Assets	46,001
Liabilities	1,507
Expenses	14,537
Revenues	0
Stockholders Equity	44,495
Net Income	-14,487
Comprehensive Net Income	-14,487
Economic Capital Ratio	261%

